Parse Biosciences , the leading provider of accessible and scalable single-cell sequencing solutions, announced the general availability of Trailmaker™, the company’s user-friendly cloud platform built for single-cell data analysis. Fast and scalable, Trailmaker provides end-to-end analysis, eliminating common analytical barriers to rapidly transform single-cell data into biological insights.
Single-cell RNA sequencing (scRNA-seq) allows researchers to gain a comprehensive and in-depth understanding of biological systems and is widely used in multiple fields, such as developmental biology, oncology, and immunology. With the widespread popularity of scRNA-seq and the expansion of experimental scale, there is an increasing need for convenient and easy-to-use data analysis methods to help researchers easily generate biological insights.
Charlie Roco, co-founder and CTO of Parse Biosciences, said: “Traditional single-cell data analysis has many challenges, including data processing, visualization, data integration and interpretation, and a lack of experts who can process the data. Our mission is to make single-cell research easier, more cost-effective, and more scalable. With Trailmaker, any researcher can easily process and analyze their single-cell data to get insights from experiments and projects faster.”
Also Read: Ori Biotech Unveils IRO Platform at Annual International Society for Cell & Gene Therapy Conference
Trailmaker ingests the unprocessed sequencing files (FASTQ) generated by the Evercode Whole Transcriptome Kit and delivers data visualization and publication-ready graphics downstream in just a few clicks, without writing any code.
The new platform is a direct result of Parse Biosciences’ acquisition of Biomage in early 2024. Already used by more than 4,500 researchers, the data analytics platform is now available free of charge to Parse Biosciences customers and all academic researchers under a new brand and with enhanced functionality.
Parse Biosciences is a global life sciences company whose mission is to accelerate human health and scientific research. The company enables researchers to perform single-cell sequencing at unprecedented scale and convenience, enabling innovative experimental approaches that are leading to breakthrough advances in cancer treatment, tissue repair, stem cell therapy, kidney and liver disease, brain development, and the immune system.
Parse was founded based on a disruptive technology developed at the University of Washington, has raised more than $100 million to date and is used by nearly 2,000 laboratories around the world. Its growing product portfolio includes Evercode Whole Transcriptome, Evercode TCR, Evercode BCR, CRISPR Detect, Gene Capture, and a data analysis software tool.
SOURCE: Businesswire